沙利度胺治疗原发性干燥综合征合并轻中度非特异性间质性肺炎疗效观察

doi:10.19723/j.issn.1671-167X.2021.02.030

Abstract

CLC Number:

R593.2

Figures/Tables 4

Table 1

Table 2

Table 3

Table 4

References 21

[1]	董笑影, 魏蔚. 沙利度胺治疗肺纤维化新进展[J]. 天津医科大学学报, 2015(3):272-274.
[2]	李丹, 刘学军, 杜毓峰. 沙利度胺治疗肺间质纤维化疗效的系统评价[J]. 国际呼吸杂志, 2014,34(14):1069-1074.
[3]	Warrick J, Bhalla M, Schabel S, et al. High resolution computed tomography in early scleroderma lung disease[J]. J Rheumatol, 1991,18(10):1520-1528. pmid: 1765976
[4]	Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2002,19(1):10-17. pmid: 12002379
[5]	郭强, 鲍春德. 结缔组织病与肺间质病变进展[J]. 上海医学, 2009,32(10):918-923.
[6]	Povysil C. Histopathological classification of idiopathic interstitial pneumonias[J]. Cesk Patol, 2010,46(1):3-7. pmid: 21280274
[7]	Kim DI, Lim YJ, Oh YH, et al. A case of Sjögren’s syndrome with multiple bullae secondary to pulmonary amyloidosis and lymphocytic infiltration of interstitium and bronchioles[J]. Tuberculosis & Respiratory Diseases, 1997,44(6):1426-1432.
[8]	Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren’s syndrome: A clinical, radiologic, and pathologic study[J]. Am J Respir Crit Care Med, 2005,171(6):632-638. pmid: 15579729
[9]	徐慧蓉, 马小兵, 王献华, 等. 肺纤维化相关因子研究进展[J]. 现代预防医学, 2011,38(10):1953-1955.
[10]	Zielonka TM. Angiogenesis in interstitial lung diseases[J]. Pneumonol Alergol Pol, 2009,77(1):52-60. pmid: 19308910
[11]	Okuma T, Terasaki Y, Kaikita K, et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases[J]. J Pathol, 2004,204(5):594-604. pmid: 15538737
[12]	Tabata C, Tabata R, Takahashi Y, et al. Thalidomide prevents cigarette smoke extract-induced lung damage in mice[J]. Int Immunopharmacol, 2015,25(2):511-517. pmid: 25749497
[13]	Arai H, Furusu A, Nishino T, et al. Thalidomide prevents the progression of peritoneal fibrosis in mice[J]. Acta Histochem Cytochem, 2011,44(2):51-60. doi: 10.1267/ahc.10030 pmid: 21614166
[14]	Leiba M, Avigdor A. Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma: Response to Moreau[J]. Br J Haematol, 2015,168(4):604-605. doi: 10.1111/bjh.13125 pmid: 25252030
[15]	李冬, 徐丽艳, 常子娟, 等. 沙利度胺对百草枯诱导小鼠急性肺损伤的干预[J]. 中华劳动卫生职业病杂志, 2013,31(3):178-183.
[16]	Buckstein R, Kerbel R, Cheung M, et al. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis[J]. Leuk Res, 2014,38(7):756-763. pmid: 24819395
[17]	Tan H, Chen H, Xu C, et al. Role of vascular endothelial growth factor in angiodysplasia: An interventional study with thalidomide[J]. J Gastroenterol Hepatol, 2012,27(6):1094-1101. pmid: 22098296
[18]	Lechtzin N, Hilliard ME, Horton MR. Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis[J]. Chest, 2013,143(6):1745-1749. pmid: 23519393
[19]	Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic, pulmonary fibrosis: A randomized trial[J]. Ann Intern Med, 2012,157(6):398-406. pmid: 22986377
[20]	Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: Predicting response to therapy and survival[J]. Am J Respir Crit Care Med, 1998,157(4 Pt 1):1063-1072. pmid: 9563720
[21]	Dixon S, Benamore R. The idiopathic interstitial pneumonias: Understanding key radiological features[J]. Clin Radiol, 2010,65(10):823-831. pmid: 20797469

Related Articles 15

[1]	Jiayi TIAN, Yixue GUO, Xia ZHANG, Xiaolin SUN, Jing HE. Flow cytometry analysis of normal range of natural killer cells and their subsets in peripheral blood of healthy Chinese adults [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 839-844.
[2]	Yushu YANG, Xuan QI, Meng DING, Wei WANG, Huifang GUO, Lixia GAO. Diagnostic values of anti-salivary gland protein-1 antibody combined with anti-parotid secretory protein antibody for Sjögren's syndrome [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 845-852.
[3]	Hua ZHONG, Yuan LI, Liling XU, Mingxin BAI, Yin SU. Application of ¹⁸F-FDG PET/CT in rheumatic diseases [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 853-859.
[4]	Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867.
[5]	Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[6]	Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734.
[7]	佳佳乔,聪田,晓波黄,军刘. [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 745-749.
[8]	Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4⁺ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[9]	Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278.
[10]	Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[11]	Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.
[12]	Yi-jun HAN,Chang-hong LI,Xiu-ying CHEN,Jin-xia ZHAO. Comparison of clinical and immunological characteristics between primary Sjögren's syndrome patients with positive and negative anti-SSB antibody [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1000-1006.
[13]	Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[14]	Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[15]	Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

Group	FVC%		FEV1%		DLco%
Group	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control (n=23)	74.99±2.13	75.99±1.95^*	72.82±1.91	74.17±2.12^*	62.75±1.89	67.43±2.75^*
Observation (n=26)	73.37±2.39	77.55±2.43^*#	72.65±1.48	75.91±1.49^*#	62.64±2.24	69.34±1.96^*#

Group	Before treatment	After treatment
Control (n=23)	9.18±2.75	7.91±2.52^*
Observation (n=26)	8.88±2.89	6.33±2.46^*#

Group	Physiology		Psychology
Group	Before treatment	After treatment	Before treatment	After treatment
Control (n=23)	5.37±0.46	5.66±0.45^*	5.29±0.52	5.53±0.51^*
Observation (n=26)	5.33±0.45	5.94±0.40^*#	5.18±0.41	5.85±0.36^*#
Group	Sociology		Total score
Group	Before treatment	After treatment	Before treatment	After treatment
Control (n=23)	5.33±0.46	5.54±0.50^*	15.99±1.15	16.74±1.17^*
Observation (n=26)	5.19±0.39	5.85±0.34^*#	15.71±1.13	17.63±0.93^*#

Group^a	Leukopenia	Stomach upset	Neurosensory abnormality	Constipation	Drowsiness
Control (n=22)	0	2 (9.1)	0	1 (4.5)	0
Observation (n=25)	1 (4.0)	2 (8.0)	1 (4.0)	3 (1.2)	6 (2.4)^*

RICH HTML

PDF (PC)

Abstract

Cite this article

share this article

Figures/Tables 4

References 21

Related Articles 15

Metrics

Comments

Recommended 0